XRTX

XORTX Therapeutics Inc.

1.95 USD
-0.15 (-7.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

XORTX Therapeutics Inc. stock is down -25% since 30 days ago. The next earnings date is Aug 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 20 June’s closed higher than May.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.